Preclinical Imaging (In-VIVO) Market - Forecast(2024 - 2030)

Report Code: HCR 0532 Report Format: PDF + Excel

Preclinical Imaging (In-VIVO) Market Overview

Preclinical Imaging (In-VIVO) Market Size is estimated to reach $1.2 billion by 2027. Furthermore, it is poised to grow at a CAGR of 5.7% over the forecast period of 2022-2027. Preclinical testing is the viewing of living animals for research purposes, such as drug development. Researchers need imaging modalities to see changes at the organ, tissue, cell, or molecular level in response to physiological or environmental changes. In order to research animal models longitudinally, non-invasive imaging methods and in-vivo are required. anatomical imaging is commonly done using high-frequency micro-ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT). molecular visualization is mainly done via optical imaging (fluorescence and bioluminescence), positron emission tomography (PET), and single-photon emission computed tomography (SPECT). Moreover, Bioluminescence imaging (BLI) is based on the sensitive detection of visible light produced during enzyme (anatomical imaging)-mediated oxidation of a molecular substrate when the enzyme is expressed in vivo as a molecular reporter. Over the last several years, the preclinical in-vivo imaging sector has seen numerous technical developments, market shifts as a result of corporate consolidation, and an increase in government funding and support for research projects all over the world.

Preclinical imaging is becoming more accepted as a viable drug research method, owing to technical breakthroughs in molecular imaging modalities is one of the key driving factors of the market. Funding issues to the National Institutes of Health (NIH) for medical research and the expensive expense of implementing advanced preclinical imaging systems are estimated to be restraining the market.

Preclinical Imaging (In-VIVO) Market Report Coverage

The report: “Preclinical Imaging (In-VIVO) Market Forecast (2022-2027)", by Industry ARC covers an in-depth analysis of the following segments of the Preclinical Imaging (In-VIVO) Market.

By Modality- Nuclear imaging, optical imaging, Micro-MRI, Micro-CT, Micro-ultrasound, Photoacoustic, Magnetic particle imaging systems.
By Reagent- MRI contrast agents, ultrasound contrast agents, CT contrast agents, optical imaging reagents, nuclear imaging reagents.
By Application - Research and development, Drug discovery.
By End Users - Hospitals & clinics, imaging centers, research organizations, and others.
By Geography- North America (U.S., Canada, Mexico), Europe (Germany, United Kingdom (U.K.), France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia, and New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), and Rest of the World (the Middle East, and Africa).

Key Takeaways

  • Geographically, North America held a dominant market share in the year 2021 on account of the increasing prevalence of cancer and people know the benefits of Preclinical Imaging (In-VIVO) and high healthcare expenditure. Asia-Pacific is estimated to offer lucrative growth opportunities to the manufacturers owing to increasing advancements in research and development. The proliferation of chronic diseases like cancer is predicted to augment the market growth during the forecast period of 2022-2027.
  • The growing prevalence of cancer is estimated to drive the market growth of the Preclinical Imaging (In-VIVO) Market. The high cost of Preclinical Imaging (In-VIVO) poses threat to the market growth.
  • A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Preclinical Imaging (In-VIVO) Market Report.

Preclinical Imaging (In-VIVO) Market: Market Share (%) by region, 2021

For more details on this report - Request for Sample

Preclinical Imaging (In-VIVO) Market Segmentation Analysis- By Modality

Preclinical Imaging (In-VIVO) Market based on modality can be further segmented into nuclear imaging, optical imaging, Micro-MRI, Micro-CT, Micro-ultrasound, Photoacoustic, Magnetic particle imaging systems. Micro-ultrasound held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 6.9% over the forecast period of 2022-2027 owing to its versatility of uses and efficacy in conducting research on tiny animal models. Micro-ultrasound is a tiny type of ultrasound that has a larger range of uses, especially in small animal model studies. Smaller versions of imaging technologies boost the efficacy of the approaches. These frequently reduce the number of animals needed for a particular investigation. Moreover, other modalities such as Micro-CT and Optical Imaging are predicted to have the fastest growth owing to the huge use of these modalities and the introduction of new technologies in these areas. MRI and PET are often utilized in preclinical imaging. A combination of imaging modalities, such as PET and CT, is frequently employed to provide high-quality results. As a result, Micro-ultrasound is dominating the market.

Preclinical Imaging (In-VIVO) Market Segmentation Analysis- By Reagent

Preclinical Imaging (In-VIVO) Market based on reagents can be further segmented into MRI contrast agents, ultrasound contrast agents, CT contrast agents, optical imaging reagents, and nuclear imaging reagents. The Ultrasound contrast agents segment held a dominant market share in the year 2021 and is estimated to be the fastest-growing, with a CAGR of 6.4% over the forecast period of 2022-2027. Technological advances that benefit animal welfare, cost-effective techniques, alternative models, the demand for medical devices, an aging population, rising health consciousness among the population, massive investments in R&D, and the growth associated with the pharmaceutical sector. The Food and Drug Administration recently authorized microbubble ultrasonic contrast agents (UCAs) for non-cardiac imaging. The physical principles of UCAs, delivery methods, dosage, side effects, and existing and future imaging approaches are all discussed. UCAs are made up of suspended microbubbles that interact strongly with the ultrasound beam and are easily seen by ultrasound imaging devices. Unlike iodinated and gadolinium contrast agents, they are limited to the blood pool when injected intravenously. Hence, the Ultrasound contrast agents segment dominates the market.

Preclinical Imaging (In-VIVO) Market Segmentation Analysis- By Geography

The Preclinical Imaging (In-VIVO) Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held a dominant market share of 35% in the year 2021 as compared to the other counterparts on account of the rising prevalence of cancer which needs further advanced research to control.

However, Asia-Pacific is estimated to be the fastest-growing over the forecast period of 2022-2027 on account of the existence of growing economies like India and China, which are embracing new technology in the medical services sector. The cost of cancer care remains to rise in Patients with chronic diseases who need to undergo diagnosis to cure the disease which radically increases the demand for medical imaging reagents.

Preclinical Imaging (In-VIVO) Market Drivers

Growing Prevalence of Chronic Diseases especially Cancer are Driving the Market

According to National Cancer Institute, in 2021, Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body. According to World Health Organization 2022, Cancer is the biggest cause of mortality globally, with approximately 10 million fatalities estimated in 2020, accounting for roughly one in every six deaths. Breast, lung, colon, rectum, and prostate cancers are the most frequent malignancies. Medical imaging has become more important in the early identification and diagnosis of cancer. In certain circumstances, medical imaging is the first step in avoiding cancer spread by early identification, and in many cases, it allows the malignancy to be cured or eliminated completely. Both CT and MR are great at imaging soft tissue structures, making them ideal for identifying and diagnosing tumors as well as determining whether they are benign or malignant. Thus, the Growing Prevalence of chronic diseases especially cancer is driving the market.

The Rising use of Imaging in Preclinical Testing is Driving the Market

The need for preclinical in-vivo imaging modalities is increasing in a variety of industries, including research and development, drug discovery, cancer cell detection, and others. The market is also being driven by a surge in investment from both the private and governmental sectors. Cellular imaging facilitates the integration of complex biology into the screening process and addresses both high-content and high-throughput needs in drug discovery. The industry's expansion is being aided by the adoption of new technologies and acquisitions done by various market participants in various parts of the world. Furthermore, important businesses are continually partnering with academic institutes, universities, and other end-users in order to impact the market's preclinical investigations. In October 2020, MR Solutions obtained a purchase order for their preclinical devices worth up to USD 10 million from prestigious universities. The top sellers among market participants were PET/CTs, PET/MRs, and 9.4T and 7T cryogen-free DRY magnets, thereby driving the market growth.

Preclinical Imaging (In-VIVO) Market Challenges

The High Price of Modalities is estimated to Restrain the Market

Globally, many institutes are unable to employ this preclinical in-vivo imaging approach owing to the high expense of modalities and research processes. According to NCBI 2019, the cost and time associated with the use of MRI as a surveillance mechanism remain a concern. Moreover, impeding market expansion is the limited use of various modalities. Furthermore, a large number of banknotes are required to set up the essential equipment and apparatus. Similarly, running costs are exorbitant, and most individuals cannot afford to pay them. The health hazards and healthcare expenses associated with the improper use of high-cost imaging such as CT scans and MRIs are causing considerable concern in the medical profession and among payers. According to estimates, up to 30% of diagnostic imaging in the United States is unnecessary. In 2014, Medicare participants had an average of 0.9 high-cost scans, and Medicare spent more than $4 billion on high-cost imaging. Due to the additional follow-up treatment that such scans can cause, total Medicare expenses from high-cost imaging are likely to be significantly higher. Hence, the high Price of Modalities is estimated to restrain the market.

Preclinical Imaging (In-VIVO) Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Preclinical Imaging (In-VIVO) Market. The top 10- Preclinical Imaging (In-VIVO) Market companies are-

  1. Aspect Imaging
  2. Biospace Lab S.A.
  3. Bruker Corporation
  4. LI-COR Biosciences
  5. Mediso Ltd.
  6. MILabs B.V.
  7. MR Solutions Ltd
  8. PerkinElmer, Inc.
  9. Intrinsic Imaging
  10. FUJIFILM VisualSonics, Inc.

Recent Developments

  • In November 2021, Fujifilm announced a new velocity MRI system. It is a high-field open MRI system, which is designed to streamline workflows and enhance the overall patient experience, by also including integrated radiofrequency coils and other reconstruction technologies. Its anatomy-conformable Synergy Flex coil is billed as the first of its kind for an open, vertical field MRI scanner, according to the company, and its open gantry offers a more spacious feeling for claustrophobic, bariatric, geriatric, and pediatric patients.
  • In July 2021, WCG announced the acquisition of Intrinsic Imaging, a significant provider of medical imaging core lab services across the world. Intrinsic Imaging strengthens WCG's scientific and regulatory capabilities, complementing the Company's suite of solutions designed to ensure data integrity and reduce risk in clinical research, with over a decade of experience, a team of more than 500 board-certified physicians, and comprehensive services in support of drug, medical device, and artificial intelligence (AI) clinical trials.
  • In February 2019, Bruker launched SKYSCANTM 1273 tabletop 3D X-ray microscope. Micro-computed tomography (Micro-CT) technology is used in the new SKYSCANTM 1273 tabletop 3D X-ray microscope. The SKYSCAN 1273 establishes a new benchmark for tabletop non-destructive testing (NDT), with performance previously only available from floor-standing devices.

Relevant Titles

Pharmacovigilance Market - Forecast(2022 - 2027)
Report Code: HCR 0401

Clinical Trial Management System Market - Forecast(2022 - 2027)
Report Code: HCR 0493

Imaging in Clinical Trials Market - Forecast(2022 - 2027)
Report Code: HCR 1296 

For more Lifesciences and Healthcare related reports, please click here

1. Preclinical Imaging (In-VIVO) Market - Overview
    1.1 Definitions and Scope
2. Preclinical Imaging (In-VIVO) Market - Executive Summary
3. Preclinical Imaging (In-VIVO) Market - Comparative Analysis
    3.1 Company Benchmarking
    3.2 Global Financial Analysis
    3.3 Market Share Analysis
    3.4 Patent Analysis
    3.5 Pricing Analysis
4. Preclinical Imaging (In-VIVO) Market - Startup Companies Scenario Premium
    4.1  Key Startup Company Analysis by
        4.1.1 Investment
        4.1.2 Revenue
        4.1.3 Venture Capital and Funding Scenario
5. Preclinical Imaging (In-VIVO) Market – Industry Market Entry Scenario Premium Premium
    5.1 Regulatory Framework Overview
    5.2 New Business and Ease of Doing Business Index
    5.3 Case Studies of Successful Ventures
6. Preclinical Imaging (In-VIVO) Market - Forces
    6.1 Market Drivers
    6.2 Market Constraints/Challenges
    6.3 Porters Five Force Model
        6.3.1 Bargaining power of suppliers
        6.3.2 Bargaining powers of customers
        6.3.3 Threat of new entrants
        6.3.4 Rivalry among existing players
        6.3.5 Threat of substitutes
7. Preclinical Imaging (In-VIVO) Market – Strategic Analysis
    7.1 Value Chain Analysis
    7.2 Opportunities Analysis
    7.3 Market Life Cycle
8. Preclinical Imaging (In-VIVO) Market – By Modality
    8.1 Nuclear imaging
    8.2 Optical imaging
    8.3 Micro-MRI
    8.4 Micro-CT
    8.5 Micro-ultrasound
    8.6 Photoacoustic
    8.7 Magnetic particle imaging systems. 
9. Preclinical Imaging (In-VIVO) Market – By Reagent
    9.1 MRI contrast agents
    9.2 Ultrasound contrast agents
    9.3 CT contrast agents
    9.4 Optical imaging reagents
    9.5 Nuclear imaging reagents
10. Preclinical Imaging (In-VIVO) Market – By Application
    10.1 Research and development
    10.2 Drug discovery
11. Preclinical Imaging (In-VIVO) Market – By End Users
    11.1 Hospitals & clinics
    11.2 Imaging centers
    11.3 Research organizations
    11.4 Others
12. Preclinical Imaging (In-VIVO) Market - By Geography
    12.1 North America
        12.1.1 U.S.
        12.1.2 Canada
        12.1.3 Mexico
    12.2 Europe
        12.2.1 U.K.
        12.2.2 Germany
        12.2.3 France
        12.2.4 Italy
        12.2.5 Spain
        12.2.6 Russia
        12.2.7 Rest of Europe
    12.3 Asia-Pacific
        12.3.1 China
        12.3.2 India
        12.3.3 Japan
        12.3.4 South Korea
        12.3.5 Australia & New Zealand
        12.3.6 Rest of Asia-Pacific
    12.4 South America
        12.4.1 Brazil
        12.4.2 Argentina
        12.4.3 Chile
        12.4.4 Colombia
        12.4.5 Rest of South America
    12.5 Rest of the World
        12.5.1 Middle East
        12.5.2 Africa
13. Preclinical Imaging (In-VIVO) Market - Entropy
14. Preclinical Imaging (In-VIVO) Market – Industry/Segment Competition Landscape Premium 
    14.1 Market Share Analysis
        14.1.1 Global Market Share – Key Companies
        14.1.2 Market Share by Region – Key companies
        14.1.3 Market Share by Countries – Key Companies
    14.2 Competition Matrix
    14.3 Best Practices for Companies
15. Preclinical Imaging (In-VIVO) Market – Key Company List by Country Premium Premium
16. Preclinical Imaging (In-VIVO) Market - Company Analysis
    16.1 Company 1
    16.2 Company 2
    16.3 Company 3
    16.4 Company 4
    16.5 Company 5
    16.6 Company 6
    16.7 Company 7
    16.8 Company 8
    16.9 Company 9
    16.10 Company 10
"*Financials for private companies would be provided on a best efforts basis”.